CJC-1295 with DAC (Drug Affinity Complex) is a long-acting GHRH analogue that binds to albumin in the bloodstream, extending its half-life to approximately 6–8 days. This allows for once-weekly dosing while maintaining elevated GH levels.
Stimulates pulsatile GH release from the anterior pituitary by mimicking endogenous GHRH. The DAC moiety extends half-life by forming a covalent bond with serum albumin, providing continuous stimulation.
Water retention, tingling or numbness (especially in hands), mild joint pain, and potential insulin resistance at higher doses.
Typical protocol: 1 mg injected SubQ once weekly. Cycle for 12–16 weeks, followed by an 8-week break.